Brian Meshkin, CEO of Proove Biosciences Inc., Receives SmartCEO Future 50 Award
- Tech stocks push S&P 500 to record close, buoy Nasdaq
- U.S. Calls for Pause of J&J (JNJ) Vaccine After Clotting Cases, Including One Death
- Coinbase (COIN) direct listing IPO reference price set at $250
- Biggest SPAC Deal Ever: Grab To Go Public in a $40 Billion Merger With Altimeter (AGC), Backed by Fidelity and BlackRock
- Oil rises after robust China data but J&J vaccine pause weighs
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
(PRWEB) March 01, 2016
Proove Biosciences, Inc., the commercial and research leader in personalized pain medicine, is excited to announce that Brian Meshkin is a winner of the SmartCEO Future 50 award. Meshkin, CEO at Proove Biosciences, is named a recipient of the prestigious award for the third straight year. The Future 50 Awards is the most prominent awards program hosted by SmartCEO magazine--and it selects leaders who embody the entrepreneurial spirit and are capable of driving economic growth.
"It is an honor and privilege to be recognized again by SmartCEO magazine," said Meshkin. Recipients of the award are forward-thinking leaders who are expected to shape the future of industry. As a result, each executive must demonstrate a three-year average of employee and revenue growth in order to be considered for the award. "We are in position to maintain our high-growth trajectory because we are making it easier than ever for doctors to make more informed decisions," said Meshkin.
With a proprietary and patented technology platform, Proove is focused on providing information that helps physicians develop customized treatment plans for every pain patient. "We are tackling pain head-on because it is the most prevalent health condition in America. We are able to identify genetic variations that indicate how a patient is likely to respond to certain treatments in advance and help avoid the dangers of prescription opioid abuse," continued Meshkin. "We know that everyone is different. As such, we understand the significance evaluating genetic variations and assessing other health-related factors that contribute to delivering customized care." Meshkin is a 2014, 2015 and 2016 of the SmartCEO recognition.
SmartCEO's mission is to educate and inspire the business community through its award- winning magazine, connections at C-level events and access to valuable online resources. SmartCEO's integrated media platforms reach decision makers in the Baltimore, New York, Philadelphia and Washington, DC, metropolitan areas.
About Proove Biosciences
Our mission is to change the future of medicine. Proove represents the proof to improve healthcare decisions. We seek to realize a future when clinicians look back and wonder how they could have ever prescribed medications without knowing how a patient would respond. Physicians use Proove Biosciences testing to improve outcomes--both safety and efficacy of medical treatment. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).
Read the full story at http://www.prweb.com/releases/2016/03/prweb13240966.htm
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Patrick Industries, Inc. Announces Pricing of Private Offering of $350 Million of Senior Notes
- CORRECTION – VectivBio Announces Closing of $146.6 Million Initial Public Offering
- INDUS Announces Fiscal 2021 First Quarter Leasing, Acquisition, Development and Disposition Updates
Create E-mail Alert Related CategoriesPress Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!